IPF
62 programs · 58 companies
Programs
62
Companies
58
Trials
67
MOAs
36
GLP-1/GIPMALT1iCAR-T CD19PCSK9iSTINGagVEGFiTYK2iSHP2iUSP1iKIF18Ai
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Phase 2/3 | TIGIT | ||
| Riboinavolisib | Phase 2/3 | GLP-1R | ||
| RHH-974 | Preclinical | JAK1 | ||
| RHH-1546 | Phase 2/3 | C5 | ||
| Ribofutibatinib | Phase 2/3 | SOS1 | ||
| SNY-4496 | Phase 2/3 | CD3 | ||
| BGN-8936 | Phase 1/2 | FXIa | ||
| BMR-1165 | Phase 2 | CD47 | ||
| 369-4107 | Phase 2 | TNFα | ||
| ROI-9675 | NDA/BLA | HER2 | ||
| RVM-3746 | Phase 1/2 | GPRC5D | ||
| RVM-274 | Phase 3 | MET | ||
| Cevicapivasertib | Phase 2 | CFTR | ||
| ZYM-2450 | Phase 2 | GLP-1R | ||
| Sovafotisoran | NDA/BLA | FGFR | ||
| Darasacituzumab | Phase 2/3 | IL-13 | ||
| Nidaosocimab | Preclinical | Aβ | ||
| BIO-3214 | Preclinical | MDM2 | ||
| INS-408 | Phase 1 | WRN | ||
| AVB-7847 | Phase 1/2 | C5 | ||
| Sovanesiran | Phase 1 | CFTR | ||
| CLL-8422 | Approved | KRASG12C | ||
| Motarasimod | Phase 1 | KIF18A | ||
| Zanulemzoparlimab | Phase 3 | AHR | ||
| Polasacituzumab | Phase 1/2 | CDK4/6 | ||
| Suramavacamten | Phase 3 | WEE1 | ||
| Pemiratamab | Phase 2/3 | TYK2 | ||
| ELI-3182 | Preclinical | PLK4 | ||
| Polarasimod | Phase 3 | GPRC5D | ||
| Pemitenlimab | Phase 3 | Tau | ||
| GEN-3979 | Phase 1 | FXIa | ||
| IVE-9723 | Phase 3 | Tau | ||
| ALD-6159 | Phase 1 | Menin | ||
| PHA-9567 | Phase 2/3 | Aβ | ||
| BBI-9525 | NDA/BLA | PLK4 | ||
| Adagrafutibatinib | Phase 3 | PCSK9 | ||
| 006-2012 | Phase 1/2 | BCL-2 | ||
| Rimarapivir | Phase 3 | PSMA | ||
| MOR-1300 | Phase 1/2 | EZH2 | ||
| Capiosocimab | Phase 1/2 | SMN2 | ||
| FER-2115 | Phase 3 | TROP-2 | ||
| Daranesiran | Approved | JAK2 | ||
| Tixasotorasib | Preclinical | BCMA | ||
| FYB-2633 | Phase 1 | MALT1 | ||
| DIV-7153 | Preclinical | TIM-3 | ||
| CAD-5301 | Phase 1/2 | BCMA | ||
| Capiderotide | NDA/BLA | PSMA | ||
| TEC-5384 | NDA/BLA | MDM2 | ||
| Liravorutinib | Approved | CD47 | ||
| Elranaritide | NDA/BLA | CD38 | ||
| AIP-7637 | NDA/BLA | GPRC5D | ||
| PRI-IIT-807 | Phase 2/3 | CD47 | ||
| WES-IIT-947 | Phase 2 | TIGIT | ||
| CAN-IIT-971 | Approved | GLP-1R | ||
| 300-6800 | Phase 1/2 | EGFR | ||
| Tirainavolisib | Approved | SHP2 | ||
| Zanusotorasib | Phase 2/3 | GPRC5D | ||
| KRK-8556 | Phase 1 | KIF18A | ||
| Miriglumide | NDA/BLA | PARP | ||
| Fixatinib | Phase 2/3 | PD-L1 | ||
| Tezeglumide | Phase 1/2 | PARP | ||
| YB-3612 | Phase 1 | HER2 |
Trials (67)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT03019567 | Zanuderotide | Phase 2/3 | Not yet recr... |
| NCT04736112 | Riboinavolisib | Phase 2/3 | Completed |
| NCT06438415 | Riboinavolisib | Phase 2/3 | Not yet recr... |
| NCT04648133 | RHH-974 | Preclinical | Completed |
| NCT03366610 | RHH-1546 | Phase 2/3 | Terminated |
| NCT06096462 | BGN-8936 | Phase 1/2 | Recruiting |
| NCT07118824 | BMR-1165 | Phase 2 | Not yet recr... |
| NCT04449029 | ROI-9675 | NDA/BLA | Completed |
| NCT03777617 | RVM-3746 | Phase 1/2 | Terminated |
| NCT03757549 | RVM-274 | Phase 3 | Not yet recr... |
| NCT03262347 | Cevicapivasertib | Phase 2 | Terminated |
| NCT04057461 | Cevicapivasertib | Phase 2 | Not yet recr... |
| NCT06577185 | ZYM-2450 | Phase 2 | Recruiting |
| NCT03957431 | Sovafotisoran | NDA/BLA | Recruiting |
| NCT07866175 | Darasacituzumab | Phase 2/3 | Completed |
| NCT03975297 | BIO-3214 | Preclinical | Active |
| NCT06252865 | BIO-3214 | Preclinical | Completed |
| NCT06176315 | Sovanesiran | Phase 1 | Active |
| NCT06408641 | CLL-8422 | Approved | Active |
| NCT04730786 | Motarasimod | Phase 1 | Completed |